Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)

BACKGROUND: Adalimumab, a biological treatment targeting tumour necrosis factor α, might be useful in sciatica. This paper describes the challenges faced when developing a new treatment pathway for a randomised controlled trial of adalimumab for people with sciatica, as well as the reasons why the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Nefyn H., Jenkins, Alison, Goulden, Nia, Hoare, Zoe, Hughes, Dyfrig A., Wood, Eifiona, Foster, Nadine E., Walsh, David, Carnes, Dawn, Sparkes, Valerie, Hay, Elaine M., Isaacs, John, Konstantinou, Kika, Morrissey, Dylan, Karppinen, Jaro, Genevay, Stephane, Wilkinson, Clare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069989/
https://www.ncbi.nlm.nih.gov/pubmed/30064491
http://dx.doi.org/10.1186/s13063-018-2801-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069989/
https://www.ncbi.nlm.nih.gov/pubmed/30064491
http://dx.doi.org/10.1186/s13063-018-2801-6

Ejemplares similares